Simplify compound efficacy studies by partnering with our experienced study directors. Our preclinical testing facility uses the Patient-Derived-Xenograft (PDX) platform to predict the effectiveness of novel or existing therapeutics on over 350 genetically characterized clinically relevant cancer models.
We offer customizable study designs, to test the effectiveness of novel or existing therapeutic compounds to advance cancer research and enable the selection of immuno-therapeutics and personalized cancer treatments. We have established and banked over 350 early passage Patient-Derived Xenograft (PDX) models that more accurately recapitulate primary human tumor biology.
Typically, cohorts of PDX-bearing NSG™ mice are randomized onto a study when tumors reach ~250 mm3. A sample standard study design, as follows, is customizable to your specifications in collaboration with your dedicated In Vivo Pharmacology Study Director and their team.
• Vehicle and drug formulated under your defined conditions
• Standard delivery methods available (IP, IV, SC, PO, ID and others possible)
• 1-5 weeks dosing period up to 21 doses per mouse
• Tumor caliper dimensions
• Body weight monitoring
• Clinical observations
• Tumor volume of 1500 mm3 or 60days post treatment initiation
• Tumors can be collected for biomarker analysis, flow cytometry, gene expression and histology
This innovative service offers a valuable preclinical testing platform for immuno-oncology, to simulate trials, evaluate multiple drugs alone or in combination, to produce predictive data. JAX In Vivo Pharmacology Services has experience engrafting primary human tumor (PDX) and cell-line tissues in humanized NSG™ mice and has the capability to evaluate immune checkpoint drugs alone or in combination.